BostonGene Named “AI-based Drug Discovery Solution of the Year” in 2025 AI Breakthrough Awards Program

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leader in AI-powered solutions for drug discovery and development, has been honored with the “AI-based Drug Discovery Solution of the Year” award in the 8^th annual AI Breakthrough Awards program. AI Breakthrough is a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market.

“BostonGene’s AI platform delivers powerful, accurate and reproducible biological signatures that represent an enhanced approach drug development - bringing precision oncology closer to clinical reality.”

Share

BostonGene’s breakthrough AI platform is transforming oncology research and drug development by integrating high throughput tissue analytics with genomic, transcriptomic and clinical data. This multimodal approach creates biological signatures, leading to improved target identification and enhanced patient stratification for clinical trials.

As part of its integrated solution, BostonGene’s novel AI-driven platform combines advanced digital pathology capabilities–such as pixel-level analysis of whole slide images–with molecular and clinical data. The insights that BostonGene’s platform delivers sharpen the precision of predictive biomarker and therapeutic target discovery.

“BostonGene’s AI platform stands out for its ability to synthesize clinical, molecular and imaging data–generating comprehensive, actionable insights that drive drug development and precision oncology,” said Steve Johansson, managing director, AI Breakthrough. “BostonGene’s AI platform delivers powerful, accurate and reproducible biological signatures that represent an enhanced approach drug development - bringing precision oncology closer to clinical reality.”

“Through our strategic collaborations with leading cancer centers and pharmaceutical companies, we are integrating advanced technology like AI into oncology care,” said Ferran Prat, PhD, JD, Chief Commercial Officer at BostonGene. “We’re grateful to AI Breakthrough for the ‘AI-based Drug Discovery Solution of the Year’ award, and we will continue to focus on using innovative AI-powered solutions to revolutionize personalized cancer treatment, expedite drug development and improve patient outcomes.”

The AI Breakthrough Awards shine a spotlight on the boldest innovators and most impactful technologies that are leading the charge in AI across a comprehensive set of categories, including Generative AI, Computer Vision, AIOps, Agentic AI, Robotics, Natural Language Processing, industry-specific AI applications and many more. This year’s program attracted more than 5,000 nominations from over 20 different countries, underscoring the explosive growth and global importance of AI as a defining technology of the 21st century.

About BostonGene Corporation

BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit www.BostonGene.com.

About AI Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including Generative AI, Machine Learning, AI Platforms, Robotics, Business Intelligence, AI Hardware, Computer Vision and more. For more information visit AIBreakthroughAwards.com.

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.